



Adenosine kinase attenuates cardiomyocyte microtubule stabilization and protects against pressure overload-induced hypertrophy and LV dysfunction

John Fassett^{a,*,1}, Xin Xu^{c,1}, Dongmin Kwak^b, Guangshuo Zhu^d, Erin K. Fassett^a, Ping Zhang^b, Huan Wang^b, Bernd Mayer^a, Robert J. Bache^a, Yingjie Chen^{a,*}

^a Department of Pharmacology and Toxicology, University of Graz, Graz 8010, Austria

^b Cardiovascular Division and Lilliehei Heart Institute, University of Minnesota, Minneapolis, MN 55455, USA

^c Department of Exercise Rehabilitation, Shanghai University of Sport, Shanghai 200438, China

^d Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

ARTICLE INFO

Keywords:

Adenosine

Adenosine kinase

Microtubules

Detyrosinated tubulin

Cardiac hypertrophy

ABSTRACT

Adenosine exerts numerous protective actions in the heart, including attenuation of cardiac hypertrophy. Adenosine kinase (ADK) converts adenosine to adenosine monophosphate (AMP) and is the major route of myocardial adenosine metabolism, however, the impact of ADK activity on cardiac structure and function is unknown. To examine the role of ADK in cardiac homeostasis and adaptation to stress, conditional cardiomyocyte specific ADK knockout mice (cADK^{-/-}) were produced using the MerCreMer-lox-P system. Within 4 weeks of ADK disruption, cADK^{-/-} mice developed spontaneous hypertrophy and increased β -Myosin Heavy Chain expression without observable LV dysfunction. In response to 6 weeks moderate left ventricular pressure overload (transverse aortic constriction; TAC), wild type mice (WT) exhibited ~60% increase in ventricular ADK expression and developed LV hypertrophy with preserved LV function. In contrast, cADK^{-/-} mice exhibited significantly greater LV hypertrophy and cardiac stress marker expression (atrial natriuretic peptide and β -Myosin Heavy Chain), LV dilation, reduced LV ejection fraction and increased pulmonary congestion. ADK disruption did not decrease protein methylation, inhibit AMPK, or worsen fibrosis, but was associated with persistently elevated mTORC1 and p44/42 ERK MAP kinase signaling and a striking increase in microtubule (MT) stabilization/detyrosination. In neonatal cardiomyocytes exposed to hypertrophic stress, 2-chloroadenosine (CADO) or adenosine treatment suppressed MT detyrosination, which was reversed by ADK inhibition with iodotubercidin or ABT-702. Conversely, adenoviral over-expression of ADK augmented CADO destabilization of MTs and potentiated CADO attenuation of cardiomyocyte hypertrophy. Together, these findings indicate a novel adenosine receptor-independent role for ADK-mediated adenosine metabolism in cardiomyocyte microtubule dynamics and protection against maladaptive hypertrophy.

1. Introduction

Adenosine exerts acute cardio-protective actions such as preconditioning [1,2] and coronary vasodilation [3], and counteracts several chronic, maladaptive processes, including inflammation [4,5], fibrosis [6], and cardiac hypertrophy [7–10]. In addition, adenosine suppresses cardiomyocyte microtubule stabilization and detyrosination [11], a cytoskeletal response to hypertrophic stress that has been shown to increase viscous load on the myofilament [12–15] and alter mechanotransduction-dependent ROS and calcium signaling [16–18]. While activation of cell surface adenosine receptors (A1, A2A, A2B, and

A3) are responsible for the vast majority of adenosine's cardioprotective effects, adenosine also exerts non-receptor-dependent actions that can protect against ischemia reperfusion injury [19] and attenuate cardiomyocyte hypertrophy [20].

Besides activating adenosine receptors, adenosine is taken up by cardiomyocytes and phosphorylated by adenosine kinase (ADK) or degraded by adenosine deaminase [21]. In support of a non-receptor-dependent mechanism of attenuating hypertrophy, adenosine (10 μ M) or 2-chloroadenosine (CADO; 5 μ M) mediated reduction of phenylephrine-induced protein synthesis and cell enlargement in neonatal rat cardiomyocytes was completely reversed by pharmacological inhibition of

* Correspondence to: Y. Chen, University of Minnesota, Mayo Mail Cod 508, 420 Delaware St. SE, Minneapolis MN55455, United States of America.

** Correspondence to: J. Fassett, University of Graz, Dept of Pharmacology and Toxicology, Humboldtstrasse 46, Graz 8010, Austria.

E-mail addresses: john.fassett@uni-graz.at (J. Fassett), chenx106@tc.umn.edu (Y. Chen).

¹ Equal contribution.

adenosine kinase (ADK) [20]. The ADK-dependent, adenosine receptor-independent attenuation of hypertrophy by exogenous adenosine in neonatal cardiomyocytes raises the intriguing possibility that ADK may exert similar growth inhibitory effects in the adult heart through metabolism of endogenous, intracellular adenosine.

Due to well-established protective effects of adenosine, ADK inhibitors are being considered as an approach to elevate interstitial adenosine levels to treat inflammatory or neurological disorders [22–24]. In the heart, ADK activity accounts for ~90% of myocardial adenosine metabolism [21] and plays a major role in regulating intracellular and extracellular adenosine concentration [25]. However, despite the important roles of adenosine in the heart, the *in vivo* impact of cardiomyocyte ADK activity and endogenous adenosine metabolism on cardiac homeostasis and hypertrophy is unknown. In this study, conditional cardiomyocyte-specific ADK knockout mice were produced to investigate the *in vivo* role of ADK in cardiac homeostasis, cytoskeletal dynamics and adaptation to left ventricular pressure overload. Additionally, pharmacological ADK inhibitors and ADK over-expression were used in neonatal rat cardiomyocytes to further examine the role of ADK and adenosine in cardiomyocyte microtubule dynamics.

2. Methods

2.1. Animals and transverse aortic constriction (TAC)

This study was approved by the Institutional Animal Care and Use Committee of University of Minnesota. Animals were housed in an air-conditioned room with a 12-h:12-h light-dark cycle, received standard rodent chow, and drank tap water. Floxed ADK mice (ADK^{f/f}) in a c57Bl6/129 background were crossed to Myh6-mer-cre-mer mice (Myh6-cre^{+/+}) [26] (Kindly provided by Jeffrey Robbins; Cincinnati Childrens Hospital), also in the c57Bl/6 background. Offspring were backcrossed to create ADK^{f/f}/Myh6-cre^{-/+} and ADK^{f/f}/Myh6-cre^{-/-} mice, which were used as breeders to produce litters of 50% ADK^{f/f}/Myh6-cre^{-/-} and 50% ADK^{f/f}/Myh6-cre^{+/+}. Male littermates were treated with tamoxifen to induce cardiomyocyte specific excision of ADK exon 7 of the ADK gene (designated cADK^{-/-}). ADK^{f/f}/Myh6-cre^{-/-} littermates treated with tamoxifen were used as controls (designated as WT). 4 weeks after the last tamoxifen injections, cADK KO and WT mice were used for sham surgery or subjected to transverse aortic constriction (TAC) as previously described [27].

2.2. Echocardiography and LV hemodynamics

Echocardiographic images were obtained using a Visual Sonics high resolution Vevo 770 system as previously described [28]. A 1.2 Fr. pressure catheter (Scisense Inc. Ontario Canada) was used to measure LV pressures. Further details are provided in the online supplement.

2.3. Western blot

Triton x-100 soluble and insoluble protein lysates of mouse ventricles were prepared as previously described [11]. The following antibodies were used: phospho-mTOR^{ser2448}, total mTOR, phospho-p70S6 kinase^{Thr389}, total p70S6 kinase, phospho-4E-BP^{Thr37/46}, total 4E-BP1, phospho-AMPK^{Thr172}, total AMPK, methyl-arginine, (Cell Signaling; Beverly, MA), ADK, (Santa Cruz Biotechnology; Santa Cruz, CA), atrial natriuretic peptide (Peninsula Biolabs; San Carlos, CA), Desmin (Abcam; Cambridge, MA), and detyrosinated tubulin (Abcam; Cambridge, MA and Upstate Biotechnology; Lake Placid, NY), β -MHC, α -sarcomeric actin, β -actin (Sigma; St Louis, MO).

2.4. Neonatal cardiomyocyte culture

NRVMs were isolated from 2 to 4 day-old Sprague-Dawley rats by enzymatic digestion and separated from non-muscle cells on a

discontinuous Percoll gradient as previously described [11]. Further details are provided in the online supplement.

2.5. MT isolation

Microtubule isolation and subcellular fractionation: Microtubule fractions were isolated from mouse ventricles in glycerol based microtubule stabilization buffer as previously described [11,14]. Further details are provided in the online supplement.

2.6. Immunostaining

NRVMs were fixed in -20 °C methanol and microtubules were detected using anti-alpha tubulin (Sigma Aldrich, St Louis, MO) and rabbit anti-detyrosinated tubulin (Abcam; Cambridge, UK), as previously described. Further details are provided in the online supplement.

2.7. Materials

2-chloroadenosine, Iodotubercidin and ABT-702 were from Tocris (Bristol;UK). Adenosine was from Sigma Aldrich.

2.8. Data and statistical analyses

All values were expressed as mean $\pm$ standard error of the mean (SEM). Statistical significance was defined as $P < .05$. One-way analysis of variance (ANOVA) was used to test each variable for differences among the treatment groups with StatView (SAS Institute Inc). If ANOVA demonstrated a significant effect, *post hoc* pairwise comparisons were made with two tailed Students *t*-test. Data that was not normally distributed were compared using the Mann-Whitney test.

3. Results

3.1. ADK disruption causes spontaneous cardiac hypertrophy

ADK^{f/f}/Myh6-cre^{-/+} and ADK^{f/f}/Myh6-cre^{-/-} mice were treated with tamoxifen to excise exon 7 and create a frameshift mutation in the ADK gene to produce cardiomyocyte specific ADK knockout mice (cADK^{-/-}) (Fig. 1A).

4 weeks after the last tamoxifen injection, ADK expression was reduced by 95% in the hearts of cADK^{-/-} mice, but unaffected in other organs (Fig. 1B). cADK^{-/-} mice developed significantly increased heart to body weight ratio (Fig. 1C), left ventricular (LV) weight, right ventricular (RV) weight, and left (LA) and right atrial (RA) weight to body weight ratios without observable effects on other organs (online supplement fig. S1A, S1B). In addition, cADK^{-/-} hearts exhibited strong expression of the cardiac hypertrophic stress marker, β -MyHC, as compared to WT mice (Fig. 1D, E). Despite the significant increase in hypertrophy in cADK^{-/-} hearts, echocardiography measurements demonstrated no difference between WT and cADK^{-/-} mice in LV chamber dimensions or function (online supplement fig. S1C).

3.2. Cardiomyocyte ADK expression attenuates pressure overload induced hypertrophy

To examine the impact of cardiomyocyte ADK expression on adaptation to hypertrophic stress, moderate pressure overload was applied to WT and cADK^{-/-} mice *via* transverse aortic constriction (TAC; 26 gauge needle, ~110 mmHg systolic aortic pressure) for 6 weeks. In comparison to WT mice, cADK^{-/-} mice developed greater TAC induced increases in left ventricular weight/BW ratio (94% in cADK^{-/-}; 70% in WT) (Fig. 2A), left atrial weight/BW (238% in cADK^{-/-}; 151% in WT) (Fig. 2B), and right ventricular weight/BW (57% in cADK^{-/-}; 35% in WT) (Fig. 2C), and (Box plots for data not normally distributed are in supplement fig. S2, A-C), indicating that in addition to increased




Fig. 1. Cardiomyocyte specific ADK disruption causes spontaneous LV hypertrophy. (A) Tamoxifen induced cardiomyocyte specific excision of floxed exon 7 in the ADK gene. (B) 4 weeks after the last tamoxifen injection, ADK protein expression was eliminated specifically in heart muscle in cADK^{-/-} mice. (C) Heart weight to body weight ratio of cADK^{-/-} and WT mice ($n = 9$ WT and 10 cADK^{-/-}). (D, E) β-MHC expression in WT and cADK^{-/-} was analyzed by western blot ($n = 4$ WT and 4 cADK^{-/-}).




Fig. 2. Cardiomyocyte ADK expression increases in response to LV pressure overload and attenuates pressure overload induced LV hypertrophy and fetal gene program. (A) LV, (B) LA, and (C) RV weight to body weight ratios in WT and cADK^{-/-} mice after 6 weeks of control or pressure overload (TAC) conditions. ($n = 26, 24, 17$, and 17 for WT, ADK^{-/-}, WT-TAC, and ADK^{-/-}-TAC, respectively) (D) Quantitation of fibrosis in LV sections from WT and cADK^{-/-} hearts ($n = 5, 5, 5$, and 5 for WT, ADK^{-/-}, WT-TAC, and ADK^{-/-}-TAC, respectively) (E, F) WGA stain and LV cardiomyocyte cross-sectional area from WT and cADK^{-/-} hearts under control or TAC conditions ($n = 5, 5, 5$, and 5 for WT, ADK^{-/-}, WT-TAC, and ADK^{-/-}-TAC, respectively) (G) Western blot and quantitation of (H), ADK (I), atrial natriuretic peptide, (J), beta myosin heavy chain (β-MHC) and (K) troponin I ($n = 5, 5, 6, 7$ for WT, ADK^{-/-}, WT-TAC, and ADK^{-/-}-TAC respectively).

basal hypertrophy, TAC-induced cardiac hypertrophy is also exaggerated in $\text{cADK}^{-/-}$ mice. At the same time, sirius red staining demonstrated no significant difference between WT and $\text{cADK}^{-/-}$ mice in myocardial fibrosis (Fig. 2D). WGA staining of heart sections revealed that $\text{cADK}^{-/-}$ cross-sectional area of $\text{cADK}^{-/-}$ cardiomyocytes was approximately 40% greater than WT cardiomyocytes under basal conditions and approximately 30% greater than WT after TAC (Fig. 2E, F), indicating that increased heart weight in $\text{cADK}^{-/-}$ mice is largely due to increased cardiomyocyte enlargement.

Interestingly, moderate TAC caused an approximate 60% increase in ADK expression in WT mice (Fig. 2G, H) and these mice exhibited only modest induction of pathological hypertrophy markers ANP and β -MHC (Fig. 2G, I, J). In contrast, $\text{cADK}^{-/-}$ hearts exhibited a striking increase in ANP and greatly exaggerated β -MHC expression in response to TAC (Fig. 2G, I, J). These data indicate that cardiomyocyte ADK expression attenuates pressure overload induced cardiomyocyte hypertrophy and activation of the fetal gene program.

3.3. $\text{cADK}^{-/-}$ mice develop LV dysfunction in response to moderate TAC

In WT mice exposed to moderate TAC, cardiac hypertrophy developed without pathologic changes in LV chamber dimensions and preserved LV ejection fraction (Fig. 3A–C). In contrast, $\text{cADK}^{-/-}$ mice developed LV dilation (Fig. 3A, B and online supplement; fig. S2D, E) and exhibited lower ejection fraction (Fig. 3C, and online supplement; fig. S2F) in response to the same stress. $\text{cADK}^{-/-}$ mice also exhibited significantly increased lung weight in comparison to WT mice, a sign of congestive heart failure (Fig. 3D, and online supplement; fig. S2G). Invasive hemodynamic measurements showed that LV end-systolic pressure increased equally in WT and $\text{cADK}^{-/-}$ mice, but LV end-diastolic pressure was significantly greater in $\text{cADK}^{-/-}$ mice, indicative of impaired LV relaxation (Fig. 3E, F). In addition, while LV relaxation rate ($-dp/dt$ min) of WT mice increased in response to moderate TAC, this was not observed in $\text{cADK}^{-/-}$ mice (Fig. 3G–H). Thus, cardiomyocyte ADK activity appears important for structural and functional adaptation to systolic overload.

3.4. ADK regulates Cardiac mTORC1 and p44/42 ERK MAP kinase signaling

Based on our previous observation that adenosine attenuates sustained mTORC1 and p44/42 ERK signaling in neonatal rat cardiomyocytes through an ADK dependent mechanism [20], we examined the potential involvement of these pathways in $\text{cADK}^{-/-}$ cardiac

hypertrophy. Phosphorylation of mTORC1 substrates $p70S6k^{\text{Thr389}}$ and $4E\text{-BP}^{\text{Ser36/47}}$ appeared higher in $\text{cADK}^{-/-}$ hearts than WT hearts under basal conditions (Fig. 4A–D). After TAC, phosphorylation of these mTOR targets increased significantly in both WT and $\text{cADK}^{-/-}$ hearts (Fig. 4A–D) and less difference in $p70S6k^{\text{Thr389}}$ phosphorylation was observed between WT and $\text{cADK}^{-/-}$ hearts, due to greater relative increase in $p70S6k$ phosphorylation in WT hearts. Phosphorylation of $4E\text{-BP}^{\text{Ser37/46}}$ however, remained significantly greater in $\text{cADK}^{-/-}$ hearts than WT hearts after TAC. Interestingly, protein levels of $p70S6k$ and $4E\text{-BP}$ were also elevated in $\text{cADK}^{-/-}$ hearts as compared to WT hearts, which accounted for much of the increased phosphorylated levels of these proteins (Fig. 4A–I). Another pro-hypertrophic signaling pathway, p44/42 ERK1/2, was also increased in $\text{cADK}^{-/-}$ hearts under both basal and TAC conditions, due to stronger p44/42 ERK1/2 expression and subsequently higher levels of phospho-p44/42 ERK $^{\text{Thr202/204}}$ (Fig. 4A, E, J). Phosphorylation of a different MAP kinase however, $p38^{\text{Thr182/Tyr184}}$, appeared slightly reduced by ADK disruption under basal conditions, and no difference was observed between $\text{cADK}^{-/-}$ and WT mice after TAC (Fig. 4A, F, K). Because cardiac mTORC1 and ERK activity promote hypertrophy [29,30], the chronic up-regulation of these signaling pathways likely contributes to the greater hypertrophy in $\text{cADK}^{-/-}$ mice. On the other hand, both of these pathways are important for physiological adaptation to pressure overload [31,32], so additional factors likely contribute to the exacerbated LV dysfunction observed in $\text{cADK}^{-/-}$ mice.

3.5. AMPK activation and protein methylation in $\text{cADK}^{-/-}$ hearts

ADK produces AMP, an activator of AMP-activated protein kinase (AMPK). AMPK inhibits mTORC1 signaling and is important for cardiac adaptation to pressure overload [33]. Phosphorylation of AMPK $^{\text{Thr172}}$ (an indicator of AMPK activation), appeared higher in $\text{cADK}^{-/-}$ hearts under basal conditions, but this was due to increased AMPK expression in $\text{cADK}^{-/-}$ hearts, so that the fraction of AMPK phosphorylated was slightly lower relative to WT hearts. No differences in AMPK phosphorylation were observed between WT and $\text{cADK}^{-/-}$ hearts after TAC (online supplement; fig. S3). High intracellular adenosine levels can inhibit S-adenosylhomocysteine hydrolase, leading to accumulation of S-adenosylhomocysteine, an inhibitor of methyltransferase reactions. ADK dependent removal of intracellular adenosine is believed to be important for maintaining methylation reactions [34]. To examine protein methylation, we measured methylated arginine levels in WT and $\text{cADK}^{-/-}$ hearts. Unexpectedly, methylated protein content was higher in $\text{cADK}^{-/-}$ hearts (online supplement; fig. S3), indicating that




Fig. 3. Effects of cardiomyocyte ADK disruption on LV function during pressure overload (A) Echocardiography measurements of end systolic diameter (ESD), (B) end diastolic diameter (EDD) and (C) ejection fraction (EF) 6 weeks after sham or TAC surgery. ($n = 10, 11, 12$, and 14 for WT, $\text{ADK}^{-/-}$, WT-TAC, and $\text{ADK}^{-/-}$ -TAC, respectively) (D) Lung weight to body weight ratio in WT and $\text{cADK}^{-/-}$ mice 6 weeks after TAC ($n = 26, 24, 17$, and 17 for, WT, $\text{ADK}^{-/-}$, WT-TAC, and $\text{ADK}^{-/-}$ -TAC, respectively). (E) Left ventricular end systolic and (F) diastolic pressures and rates of LV pressure development during (G) systole and (H) diastole in WT and $\text{cADK}^{-/-}$ mice after TAC. ($n = 8, 9, 6$, and 10 for WT, $\text{ADK}^{-/-}$, WT-TAC, and $\text{ADK}^{-/-}$ -TAC, respectively).




Fig. 4. Cardiac mTORC1 and p44/42 ERK MAP kinase pathways are upregulated by ADK disruption (A–B) 6 weeks after TAC or sham surgeries, WT and cADK^{-/-} ventricular lysates were analyzed by western blot for phosphorylated and total levels of mTOR^{Ser2448} (A, B, G), p70S6k^{Thr389} (A, C, H), 4EBP^{Thr37/46} (A, D, I) MAP kinases ERK^{Thr202/Tyr204} (A, E, J) and p38^{Thr180/Tyr182} (A, F, K) in WT and cADK^{-/-} ventricular lysates under control and TAC conditions. (n = 5, 5, 6, and 7 for WT, cADK^{-/-}, WT-TAC, and cADK^{-/-}-TAC respectively).

insufficient methylation does not underlie the maladaptive cardiac phenotype of cADK^{-/-} mice.

3.6. ADK regulation of cardiomyocyte microtubules

Previously, we demonstrated that extracellular adenosine attenuates cardiomyocyte microtubule stabilization and can decrease detyrosinated tubulin content [11]. Microtubule stabilization/accumulation has been shown to contribute to cardiomyocyte contractile dysfunction in the setting of pressure overload [11,13,14,35,36] and recently, microtubule detyrosination was implicated in cardiomyocyte contractile impairment in human heart failure of multiple etiologies [15]. Levels of non-polymerized (Free) tubulin and cold labile, dynamic microtubules (MTs) represent approximately 50% and 30–40% of total tubulin, respectively, in mouse heart microtubule preparations. Cold stable, triton soluble MTs associated with the cell membrane fraction (memb), and triton insoluble cytoskeletal fractions (CSK), represent approximately 10–15% and 2–5% respectively, of the remaining pools of tubulin. Tubulin levels in the membrane and cytoskeletal fractions increase significantly in pressure overload induced heart failure and correlate strongly with LV dysfunction [37]. Under basal conditions, cADK^{-/-} and WT hearts exhibited no significant differences in Free and cold-labile MTs (Fig. 5B–D), but did exhibit significantly greater levels of membrane-associated tubulin (Fig. 5B, E) and CSK tubulin (Fig. 5B, F) than WT hearts. In response to moderate TAC, WT hearts did not exhibit a significant increase in tubulin in any subcellular MT fraction (Fig. 5B–F). In cADK^{-/-} hearts, cold-labile microtubules (MTs) increased to a significantly higher level than WT hearts (Fig. 5B, D) and the difference between WT and cADK^{-/-} hearts in membrane associated tubulin levels also became slightly greater after TAC.

Detyrosination of alpha tubulin is a post-translational modification of long-lived microtubules [38] that has been shown to alter subcellular

trafficking [39,40], disturb calcium dynamics [17], and increase mechanical load on the myofilament [13,15]. Western blot analysis revealed significantly greater levels of detyrosinated tubulin in cADK^{-/-} hearts than WT hearts (Fig. 5G–K), particularly in the MT, Memb, and CSK fractions after TAC. These findings indicate that ADK activity attenuates cardiac microtubule stabilization and detyrosination and prevents aberrant subcellular MT distribution. The extent to which MTs are detyrosinated is generally believed to be a function of their longevity. However, changes in expression of tubulin carboxypeptidases and tubulin tyrosine ligases [41], the enzymes which directly modify tubulin tyrosination, might also contribute to altered levels of detyrosinated tubulin. Therefore, we examined the expression of Vash1 (VASH1), a recently identified tubulin carboxypeptidase [42,43], and tubulin tyrosine ligase in WT and cADK^{-/-} hearts. Western blot analysis revealed no significant changes in expression of VASH1, while TTL levels were increased in cADK^{-/-} hearts under basal conditions and trended higher after TAC (online supplement fig. S4). These results indicate that ADK-mediated changes in microtubule detyrosination are not likely due to changes in expression levels of the known tubulin tyrosine regulating proteins.

In addition to increasing cardiac microtubule stability, ADK disruption also increased levels of cytoskeletal proteins, β -actin and desmin under basal conditions (Fig. 5L–N). While β -actin content became equivalent in cADK^{-/-} and WT hearts after TAC, due to a significant increase only in WT hearts (Fig. 5L, M), desmin levels increased significantly above basal levels in cADK^{-/-} hearts (Fig. 5L, N).

3.7. Adenosine metabolism by ADK diminishes detyrosinated microtubules

To further define the role(s) of ADK and adenosine in cardiomyocyte microtubule dynamics, we used a neonatal cardiomyocyte hypertrophy model, in which phenylephrine promotes hypertrophy and microtubule




Fig. 5. ADK disruption increases microtubule stabilization/detyrosination (A) Ventricular lysates were separated into different Free, Microtubule (MT), Membrane (Memb), and Cytoskeletal (CSK) fractions as depicted. (N is nucleus, G is golgi, SR is sarcoplasmic reticulum, TT is t-tubules, M is mitochondria, SL is sarcolemma, MT is microtubule, sMT is stabilized microtubule) MyF is myofibril, and IF is intermediate filament. Cardiac lysates were analyzed by western blot for alpha tubulin (B–F) and detyrosinated tubulin (Glu-tubulin) (G–K). β -actin (L, M), desmin (L, N) and sarcomeric actin (L, O), were also measured in the triton insoluble cytoskeletal fraction. (n = 4, 4, 5, and 6 for WT, cADK^{-/-}, WT-TAC, and cADK^{-/-} TAC respectively).

stabilization/detyrosination [11]. As previously demonstrated [11], co-treatment with 2-chloroadenosine (CADO; an adenosine deaminase resistant adenosine analogue) has little effect on free tubulin (Fig. 6A, B) but attenuates the phenylephrine-induced increases in triton insoluble cytoskeletal (CSK) tubulin as well as detyrosinated tubulin (glu-tubulin), as indicated by western blot analysis (Fig. 6A, C, D, E). Inhibition of ADK activity using iodotubercidin (ITU; 0.3 μ M) significantly reversed the effects of CADO on microtubules, particularly in the cytoskeletal fraction (6C–E). Interestingly, while adenosine receptor antagonism using 8-phenyltheophylline (8-PT) appeared to block CADO reduction of CSK tubulin, it did not block CADO reduction of detyrosinated tubulin (Fig. 6A–E) and (Supplementary data Fig. S6A). Immunofluorescent analysis (Fig. 6F) also showed that CADO suppression of microtubule detyrosination was reversed by ITU, but not by adenosine receptor antagonism with 8-PT. In addition, selective A1, A2A, and A2B adenosine receptor antagonists were ineffective at blocking CADO effects on MTs, and A3 receptor antagonism actually appeared to potentiate CADO inhibition of MT stability. (Supplementary data S5A–H). These results indicate that ADK activity mediates CADO destabilization of MTs. Similar to CADO, 10 μ M adenosine reduced levels of detyrosinated MTs, and this was reversed by ABT-702 (Supplementary data S6B) an ADK inhibitor mechanistically distinct from ITU. To examine the potential of CADO to diminish detyrosinated MTs, independent of its anti-hypertrophic actions, we allowed cardiomyocytes to hypertrophy for 48 h, and then added CADO for an additional 24 h.

Importantly, CADO treatment depleted detyrosinated MTs without significantly affecting cell area, and this was blocked by ADK inhibition with ABT-702 (Fig. 6C, D). These results suggest adenosine metabolism by ADK can re-establish dynamic MTs in hypertrophied cardiomyocytes and these effects occur independently from adenosine attenuation of hypertrophy.

To further examine the role of ADK in MT dynamics, ADK was over-expressed in cardiomyocytes using adenovirus. Over-expression of ADK had no significant effect on total α -tubulin levels in the soluble or CSK fraction as compared to β -gal infected cells (Fig. 7A, B, C), but did enhance CADO induced reductions in cytoskeletal tubulin (Fig. 7A, C) and detyrosinated tubulin within the soluble fraction (Fig. 7A, D). At the same time, ADK had little observable effect on desmin or β -actin polymerization (Fig. 7A). Interestingly, immunofluorescent analysis demonstrated that ADK over-expression, even in absence of exogenous adenosine, promoted microtubule disorganization that was characterized by reduced microtubule alignment and failure of detyrosinated MTs to extend into the cytosol (Fig. 7F), suggesting ADK regulates both cardiomyocyte MT stability and MT organization. Because microtubule organization plays an important role in cell enlargement, we examined how ADK over-expression impacts cardiomyocyte hypertrophy. Interestingly, ADK over-expression limited phenylephrine induced cardiomyocyte enlargement in absence of exogenous adenosine, and potentiated CADO attenuation of cell enlargement, while ADK inhibition with ABT-702 mostly reversed the effects of CADO (Fig. 7G). These data




Fig. 6. Pharmacological inhibition of ADK reverses CADO attenuation of microtubule stabilization/detyrosination. (A) Neonatal cardiomyocytes (NRVMs) were treated with phenylephrine (50 μM) for 48 h in presence of CADO (5 μM), CADO + non-selective adenosine receptor antagonist 8-PT (10 μM), or CADO + ADK inhibitor iodotubercidin (ITU; 0.3 μM). α-tubulin (B and C) and detyrosinated α-tubulin (glu-tubulin) (D and E) were measured by western blot in triton soluble (sol) (B and D) and insoluble (CSK) (C and E) fractions ($n \geq 4$ per condition). * indicates $p < .05$ compared to PE. # indicates $p < .05$ compared to PE-CADO. (F) Immunofluorescence staining of NRVMs for α-tubulin and glu-tubulin after treatment described above. (G) NRVMs were treated with PE for 48 h to induce hypertrophy, followed by an additional 24 h with PE, PE + CADO, or PE + CADO + ABT-702(0.3 μM). α-tubulin and glu-tubulin were visualized by immunofluorescence and the area of detyrosinated tubulin was divided by the area of total tub (H) in 25–30 cells per condition. Percent change in cell area was also measured (J). Results are the average of 3 experiments, relative to continued PE treatment alone.

indicate that ADK metabolism of adenosine attenuates microtubule stabilization and hypertrophy in cardiomyocytes.

4. Discussion

This study identifies a novel role for ADK-dependent adenosine metabolism in cardiomyocyte homeostasis and functional adaptation to LV pressure overload. Cardiomyocyte-specific ADK knockout caused cardiomyocyte hypertrophy under basal conditions and significantly exacerbated TAC induced hypertrophy and LV dysfunction. In addition to increasing mTORC1 and ERK signaling, ADK disruption promoted microtubule detyrosination, a post-translational microtubule modification observed in human heart failure of multiple etiologies that is believed to impair cardiomyocyte contractility [13,15]. Thus ADK activity, ostensibly through its phosphorylation of adenosine, plays a homeostatic role in the heart, dampening both cardiac growth signaling (mTORC1 and ERK) and excessive microtubule stabilization/detyrosination. Together, these findings identify ADK as a novel regulator of cardiomyocyte microtubule dynamics that protects against pathological hypertrophy.

While the specific molecular mechanisms underlying ADK

attenuation of cardiac hypertrophy are unclear, ADK down-regulation of mTORC1 signaling is likely a contributing factor. mTORC1 is a protein complex which activates p70S6 kinase and inhibits 4E-BP, facilitating ribosomal biogenesis, protein translation, and other anabolic actions [31,44]. mTORC1 activity is necessary for compensatory hypertrophy [32] and inhibition of mTORC1 signaling with rapamycin has been shown to attenuate pressure overload induced cardiac hypertrophy [29]. The finding that ADK disruption increased mTORC1 activity is consistent with our previous findings in neonatal cardiomyocytes showing that CADO-mediated inhibition of mTORC1 signaling was restored by ADK inhibition with iodotubercidin [20]. However, unlike our findings in cultured cells, much of the increase in mTORC1 signaling in $cADK^{-/-}$ hearts appeared due to increased expression level of mTORC1 signaling components. In addition to regulating anabolic signaling in the heart, ADK activity limits mTORC1 signaling in the pancreas, where *in vivo* administration of ADK inhibitors promote islet beta cell replication [45]. p44/42 ERK MAP kinase was also up-regulated in $cADK^{-/-}$ hearts at the protein level, resulting in constitutively higher phosphorylated ERK content. Both ERK and mTORC1 signaling promote cardiac hypertrophy [29,30] but also protect against cell death and preserve cardiac function in the setting of pressure




Fig. 7. ADK adenovirus augments CADO suppression of microtubule stabilization/detyrosination. (A) Neonatal cardiomyocytes (NRVMs) were infected with β-gal or ADK expressing adenovirus (adv) for 24 h prior to treatment with PE for 48 h in the presence or absence of CADO (5 μM). Soluble (A, B, D) and cytoskeletal fractions (B, C, E) were examined by western blot for α-tubulin and glu-tubulin. CADO + non-selective adenosine receptor antagonist 8-PT (10 μM), or CADO + ADK inhibitor iodotubercidin (ITU; 0.3 μM). α-tubulin (B and C) and detyrosinated α-tubulin (glu-tubulin) (D and E) were measured by western blot in triton soluble (sol) (B and D) and insoluble (CSK) (C and E) fractions (n ≥ 4 per condition).

* indicates $p < .05$ compared to PE. † indicates $p < .05$ compared to PE-CADO. (F) NRVMs infected with β-gal or ADK adv were examined by immunofluorescence for α-tubulin and glu-tubulin. (G) Cell area was measured in NRVMs infected with β-gal or ADK adv 48 h after treatment with PE, PE + 1, 5, or 10 μM CADO, or PE + 5 μM CADO + 0.3 μM ABT-702. (Bars represent the average cell area of at least 100 cells measured per condition; * indicates $p < .05$ compared to PE. † indicates $p < .05$ compared to PE-CADO. # indicates $p < .05$ comparing ADK adv to β-gal adv under same treatment).

overload [32,46,47]. Thus, activation of these pathways may contribute to increased hypertrophy and enhanced activation of the fetal gene program in $cADK^{-/-}$ hearts, but their known cardio-protective actions suggest they are not likely the primary cause of $cADK^{-/-}$ LV dysfunction.

A more likely factor in the LV dysfunction observed in $cADK^{-/-}$ mice after pressure overload is increased stabilization and accumulation of cardiac microtubules. Cardiomyocyte microtubule densification is induced by ventricular pressure overload in many animal species [48] [35]^{11,12} and is also observed in samples from patients in end stage heart failure.^{49,50} Recently, the impact of cardiac microtubule stabilization on LV function has gained more recognition, as elegant live cell microtubule imaging and single cell measurements of contractility have specifically identified detyrosinated microtubules as a source of mechanical impairment in cardiomyocytes isolated from mouse or human failing hearts.^{13,15} $cADK^{-/-}$ hearts exposed to TAC exhibit reduced ejection fraction and impaired relaxation, which are consistent with an increase in cardiomyocyte viscosity. The finding that TAC-induced fibrosis was not worsened by ADK disruption suggests cell death or inflammation were not exacerbated by ADK disruption and points towards an intra-cardiomyocyte mechanism of impaired contractility. In addition to increasing myofilament load, stabilized microtubules can dysregulate stretch induced calcium dynamics through a process known as X-ROS signaling.^{17,18} Pressure overload induced microtubule

stabilization can also interfere with trafficking of junctophilin to the SR, leading to disrupted SR architecture and altered calcium dynamics.³⁶ Thus, aberrant MT stabilization/redistribution in $cADK^{-/-}$ hearts could impair contractility through dysregulated calcium handling and/or increased viscous load. In support of a maladaptive role for pressure overload-induced subcellular redistribution of MTs, our lab observed that tubulin accumulation in the membrane and cytoskeletal fractions of ventricular MT preparations correlated strikingly with impaired LV function during pressure overload.³⁷ The finding that ventricular ADK expression increased in response to moderate TAC suggests an adaptive role for ADK in preservation of normal MT dynamics during cardiac stress, as WT mice showed almost no increase in microtubule stabilization or redistribution and no impairment of LV function in response to TAC. Loss of ADK activity on the other hand, increased MT stabilization, detyrosination, and subcellular redistribution, even in absence of stress.

Interestingly, despite having increased detyrosinated microtubules under basal conditions, LV dysfunction was not observed in $cADK^{-/-}$ hearts until pressure overload was applied. This might argue against a prominent role for MT detyrosination in contractile impairment. However, it is possible that the spontaneous hypertrophy observed in $cADK^{-/-}$ hearts developed, in part, as a compensatory response to overcome MT induced contractile impairment. Notably, cardiac hypertrophy was also observed in a transgenic mouse model expressing a

microtubule stabilizing tubulin mutation in the heart.¹² In addition, cADK^{-/-} hearts exhibited increased levels of desmin and β -actin under basal conditions, while desmin expression was further increased in cADK^{-/-} hearts after TAC. A previous study showed that exogenously expressed β -actin can increase adult cardiomyocyte contractility.⁵¹ Interactions between sarcomeric desmin and detyrosinated MTs, however, are believed to increase viscous load on myofilaments.¹³ Increased desmin levels accompanied by increased detyrosinated tubulin in cADK^{-/-} hearts after TAC may also contribute to the observed LV dysfunction in these mice.

In cultured neonatal cardiomyocytes, treatment with adenosine or 2-CADO reduced detyrosinated microtubules through an ADK dependent mechanism. Together, with the observation of increased MT stability and redistribution in cADK^{-/-} hearts, these findings suggest ADK metabolism of endogenous, intracellular adenosine, and presumably, production of AMP, limits MT stabilization to maintain MT dynamics. Though we previously demonstrated that AMPK can attenuate microtubule stabilization⁵², AMPK phosphorylation was only modestly affected in cADK^{-/-} hearts. Expression of tubulin tyrosine ligase and vasohibin1, enzymes that mediate tubulin re-tyrosination or MT detyrosination, respectively, also were not altered in cADK^{-/-} hearts in a manner that would promote MT detyrosination. Our findings that ADK disruption increases cardiac MT stability and alters subcellular tubulin distribution *in vivo*, and that over-expression of ADK causes MT disorganization in NRVMs (in addition to reducing detyrosinated tubulin), suggests ADK activity may modulate the function of a protein(s) that modulates both MT stability and tracking. Because ADK is localized in the nucleus in cardiomyocytes, and extracellular adenosine is converted to ATP in the nucleus⁵³, we hypothesize that ADK may modulate MT stability by regulating the activity of a perinuclear MT-depolymerizing kinesin or other MT-associated protein that is sensitive to changes in perinuclear adenine nucleotides. The molecular mechanism(s) underlying the striking effects of ADK-mediated adenosine metabolism on microtubules and cardiomyocyte hypertrophy will be the subject of future studies.

5. Conclusion

ADK activity attenuates cardiac hypertrophy and is important for physiological adaptation to pressure overload. ADK activity also mediates adenosine suppression of microtubule stability/detyrosination, suggesting a novel link between adenosine recycling and microtubule dynamics. Strategies to increase myocardial adenosine metabolism by ADK could therefore provide a new approach to attenuate cardiomyocyte microtubule detyrosination, limit hypertrophy, and improve cardiomyocyte contractility in the failing heart.

Financial support

HL20598, HL21872 and HL71790 from the National Heart, Lung, and Blood Institute. Drs Zhang, Fasset are recipients of Scientist Development Awards from the American Heart Association. Drs. Fasset and Mayer are recipients of an Austrian Science Foundation grant, FWF Project P 31083-B34.

Disclosures

The authors have no conflicts of interests to disclose.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jmcc.2019.03.015>.

References

- [1] N.V. Solenkova, V. Solodushko, M.V. Cohen, J.M. Downey, Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt, *Am. J. Physiol. Heart Circ. Physiol.* 290 (2006) H441–H449.
- [2] J.P. Headrick, R.D. Lasley, Adenosine receptors and reperfusion injury of the heart, *Handb. Exp. Pharmacol.* (2009) 189–214.
- [3] S.J. Mustafa, R.R. Morrison, B. Teng, A. Pelleg, Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology, *Handb. Exp. Pharmacol.* (2009) 161–188.
- [4] G. Hasko, P. Pacher, A2A receptors in inflammation and injury: lessons learned from transgenic animals, *J. Leukoc. Biol.* 83 (2008) 447–455.
- [5] J. Linden, C. Cekic, Regulation of lymphocyte function by adenosine, *Arterioscler. Thromb. Vasc. Biol.* 32 (2012) 2097–2103.
- [6] R.K. Dubey, D.G. Gillespie, E.K. Jackson, Adenosine inhibits collagen and protein synthesis in cardiac fibroblasts: role of A2B receptors, *Hypertension* 31 (1998) 943–948.
- [7] Y. Liao, S. Takashima, Y. Asano, M. Asakura, A. Ogai, Y. Shintani, T. Minamino, H. Asanuma, S. Sanada, J. Kim, H. Ogita, H. Tomoike, M. Hori, M. Kitakaze, Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model, *Circ. Res.* 93 (2003) 759–766.
- [8] Y. Sassi, A. Ahles, D.J. Truong, Y. Baqi, S.Y. Lee, B. Husse, J.S. Hulot, A. Foinquinos, T. Thum, C.E. Muller, A. Dendorfer, B. Laggenbauer, S. Engelhardt, Cardiac myocyte-secreted cAMP exerts paracrine action via adenosine receptor activation, *J. Clin. Invest.* 124 (2014) 5385–5397.
- [9] X. Xu, J. Fasset, X. Hu, G. Zhu, Z. Lu, Y. Li, J. Schnermann, R.J. Bache, Y. Chen, Ecto-5'-nucleotidase deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction, *Hypertension* 51 (2008) 1557–1564.
- [10] Z. Lu, J. Fasset, X. Xu, X. Hu, G. Zhu, J. French, P. Zhang, J. Schnermann, R.J. Bache, Y. Chen, Adenosine A3 receptor deficiency exerts unanticipated protective effects on the pressure-overloaded left ventricle, *Circulation* 118 (2008) 1713–1721.
- [11] J.T. Fasset, X. Xu, X. Hu, G. Zhu, J. French, Y. Chen, R.J. Bache, Adenosine regulation of microtubule dynamics in cardiac hypertrophy, *Am. J. Physiol. Heart Circ. Physiol.* 297 (2009) H523–H532.
- [12] G. Cheng, M.R. Zile, M. Takahashi, C.F. Baicu, D.D. Bonnem, F. Cabral, D.R. Menick, Gt Cooper, A direct test of the hypothesis that increased microtubule network density contributes to contractile dysfunction of the hypertrophied heart, *Am. J. Physiol. Heart Circ. Physiol.* 294 (2008) H2231–H2241.
- [13] P. Robison, M.A. Caporizzo, H. Ahmadzadeh, A.I. Bogush, C.Y. Chen, K.B. Margulies, V.B. Shenoy, B.L. Prosser, Detyrosinated microtubules buckle and bear load in contracting cardiomyocytes, *Science* 352 (2016) aaf0659.
- [14] H. Tsutsui, K. Ishihara, Gt Cooper, Cytoskeletal role in the contractile dysfunction of hypertrophied myocardium, *Science* 260 (1993) 682–687.
- [15] C.Y. Chen, M.A. Caporizzo, K. Bedi, A. Vite, A.I. Bogush, P. Robison, J.G. Heffler, A.K. Salomon, N.A. Kelly, A. Babu, M.P. Morley, K.B. Margulies, B.L. Prosser, Suppression of detyrosinated microtubules improves cardiomyocyte function in human heart failure, *Nat. Med.* 24 (8) (2018) 1225–1233.
- [16] Hong TT, Smyth JW, Gao D, Chu KY, Vogan JM, Fong TS, Jensen BC, Colecraft HM and Shaw RM. BIN1 localizes the L-type calcium channel to cardiac T-tubules. *PLoS Biol.* 8:e1000312.
- [17] B.L. Prosser, R.J. Khairallah, A.P. Ziman, C.W. Ward, W.J. Lederer, X-ROS signaling in the heart and skeletal muscle: stretch-dependent local ROS regulates [Ca²⁺]_i, *J. Mol. Cell. Cardiol.* 58 (2013) 172–181.
- [18] J.P. Kerr, P. Robison, G. Shi, A.I. Bogush, A.M. Kempema, J.K. Hexum, N. Becerra, D.A. Harki, S.S. Martin, R. Raiteri, B.L. Prosser, C.W. Ward, Detyrosinated microtubules modulate mechanotransduction in heart and skeletal muscle, *Nat. Commun.* 6 (2015) 8526.
- [19] J. Peart, L. Willems, J.P. Headrick, Receptor and non-receptor-dependent mechanisms of cardioprotection with adenosine, *Am. J. Physiol. Heart Circ. Physiol.* 284 (2003) H519–H527.
- [20] J.T. Fasset, X. Hu, X. Xu, Z. Lu, P. Zhang, Y. Chen, R.J. Bache, Adenosine kinase regulation of cardiomyocyte hypertrophy, *Am. J. Physiol. Heart Circ. Physiol.* 300 (2011) H1722–H1732.
- [21] K. Kroll, U.K. Decking, K. Dreikorn, J. Schrader, Rapid turnover of the AMP-adenosine metabolic cycle in the Guinea pig heart, *Circ. Res.* 73 (1993) 846–856.
- [22] D.L. Boyle, E.A. Kowaluk, M.F. Jarvis, C.H. Lee, S.S. Bhagwat, M. Williams, G.S. Firestein, Anti-inflammatory effects of ABT-702, a novel non-nucleoside adenosine kinase inhibitor, in rat adjuvant arthritis, *J. Pharmacol. Exp. Ther.* 296 (2001) 495–500.
- [23] N.M. Elsherbiny, S. Ahmad, M. Naime, A.M. Elsherbiny, S. Fulzele, M.M. Al-Gayyar, L.A. Eissa, M.M. El-Shishtawy, G.I. Liou, ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy, *Life Sci.* 93 (2013) 78–88.
- [24] D. Boison, Adenosine kinase: exploitation for therapeutic gain, *Pharmacol. Rev.* 65 (2013) 906–943.
- [25] A. Deussen, M. Stappert, S. Schafer, M. Kelm, Quantification of extracellular and intracellular adenosine production: understanding the transmembrane concentration gradient, *Circulation* 99 (1999) 2041–2047.
- [26] D.S. Sohal, M. Nghiem, M.A. Crackower, S.A. Witt, T.R. Kimball, K.M. Tymitz, J.M. Penninger, J.D. Molkentin, Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein, *Circ. Res.* 89 (2001) 20–25.
- [27] P. Hu, D. Zhang, L. Swenson, G. Chakrabarti, E.D. Abel, S.E. Litwin, Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling

- during pressure overload, *Am. J. Physiol. Heart Circ. Physiol.* 285 (2003) H1261–H1269.
- [28] R.J. Khairallah, G. Shi, F. Sbrana, B.L. Prosser, C. Borroto, M.J. Mazaitis, E.P. Hoffman, A. Mahurkar, F. Sachs, Y. Sun, Y.W. Chen, R. Raiteri, W.J. Lederer, S.G. Dorsey, C.W. Ward, Microtubules underlie dysfunction in duchenne muscular dystrophy, *Sci. Signal.* 5 (2012) ra56.
- [29] T. Shioi, J.R. McMullen, O. Tarnavski, K. Converso, M.C. Sherwood, W.J. Manning, S. Izumo, Rapamycin attenuates load-induced cardiac hypertrophy in mice, *Circulation* 107 (2003) 1664–1670.
- [30] O.F. Bueno, L.J. De Windt, K.M. Tymitz, S.A. Witt, T.R. Kimball, R. Kleivitsky, T.E. Hewett, S.P. Jones, D.J. Lefer, C.F. Peng, Kitsis RN and Molkentin JD. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice, *EMBO J.* 19 (2000) 6341–6350.
- [31] S. Sciarretta, M. Volpe, J. Sadoshima, Mammalian target of rapamycin signaling in cardiac physiology and disease, *Circ. Res.* 114 (2014) 549–564.
- [32] D. Zhang, R. Contu, M.V. Latronico, J. Zhang, R. Rizzi, D. Catalucci, S. Miyamoto, K. Huang, M. Ceci, Y. Gu, N.D. Dalton, K.L. Peterson, K.L. Guan, J.H. Brown, J. Chen, N. Sonenberg, G. Condorelli, mTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice, *J. Clin. Invest.* 120 (2010) 2805–2816.
- [33] P. Zhang, X. Hu, X. Xu, J. Fasset, G. Zhu, B. Viollet, W. Xu, B. Wiczor, D.A. Bernlohr, R.J. Bache, Y. Chen, AMP activated protein kinase- α 2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice, *Hypertension*. 52 (2008) 918–924.
- [34] D. Boison, L. Scheurer, V. Zumsteg, T. Rulicke, P. Litynski, B. Fowler, S. Brandner, H. Mohler, Neonatal hepatic steatosis by disruption of the adenosine kinase gene, *Proc. Natl. Acad. Sci. U. S. A.* 99 (2002) 6985–6990.
- [35] H. Tagawa, M. Koide, H. Sato, M.R. Zile, B.A. Carabello, Gt Cooper, Cytoskeletal role in the transition from compensated to decompensated hypertrophy during adult canine left ventricular pressure overloading, *Circ. Res.* 82 (1998) 751–761.
- [36] C. Zhang, B. Chen, A. Guo, Y. Zhu, J.D. Miller, S. Gao, C. Yuan, W. Kutschke, K. Zimmerman, R.M. Weiss, X.H. Wehrens, J. Hong, F.L. Johnson, L.F. Santana, M.E. Anderson, L.S. Song, Microtubule-mediated defects in Juncophilin-2 trafficking contribute to myocyte T-tubule remodeling and Ca²⁺ handling dysfunction in heart failure, *Circulation* 129 (17) (2014) 1742–1750.
- [37] J.T. Fasset, X. Xu, D. Kwak, H. Wang, X. Liu, X. Hu, R.J. Bache, Y. Chen, Microtubule actin Cross-linking factor 1 regulates cardiomyocyte microtubule distribution and adaptation to hemodynamic overload, *PLoS One* 8 (2013) e73887.
- [38] G.G. Gundersen, J.C. Bulinski, Microtubule arrays in differentiated cells contain elevated levels of a post-translationally modified form of tubulin, *Eur. J. Cell Biol.* 42 (1986) 288–294.
- [39] S. Dunn, E.E. Morrison, T.B. Liverpool, C. Molina-Paris, R.A. Cross, M.C. Alonso, M. Peckham, Differential trafficking of Kif5c on tyrosinated and detyrosinated microtubules in live cells, *J. Cell Sci.* 121 (2008) 1085–1095.
- [40] S.X. Lin, G.G. Gundersen, F.R. Maxfield, Export from pericentriolar endocytic recycling compartment to cell surface depends on stable, detyrosinated (glu) microtubules and kinesin, *Mol. Biol. Cell* 13 (2002) 96–109.
- [41] J. Nieuwenhuis, T.R. Brummelkamp, The tubulin detyrosination cycle: function and enzymes, *Trends Cell Biol.* 29 (2019) 80–92.
- [42] C. Aillaud, C. Bosc, L. Peris, A. Bosson, P. Heemeryck, J. Van Dijk, J. Le Fric, B. Boulan, F. Vossier, L.E. Sanman, S. Syed, N. Amara, Y. Coute, L. Lafanechere, E. Denarier, C. Delphin, L. Pelletier, S. Humbert, M. Bogoy, A. Andrieux, K. Rogowski, M.J. Moutin, Vasohibins/SVBP are tubulin carboxypeptidases (TCPs) that regulate neuron differentiation, *Science* 358 (2017) 1448–1453.
- [43] J. Nieuwenhuis, A. Adamopoulos, O.B. Bleijerveld, A. Mazouzi, E. Stickel, P. Celie, M. Altelaar, P. Knipscheer, A. Perrakis, V.A. Blomen, T.R. Brummelkamp, Vasohibins encode tubulin detyrosinating activity, *Science* 358 (2017) 1453–1456.
- [44] I. Ben-Sahra, B.D. Manning, mTORC1 signaling and the metabolic control of cell growth, *Curr. Opin. Cell Biol.* 45 (2017) 72–82.
- [45] J.P. Annes, J.H. Ryu, K. Lam, P.J. Carolan, K. Utz, J. Hollister-Lock, A.C. Arvanites, L.L. Rubin, G. Weir, D.A. Melton, Adenosine kinase inhibition selectively promotes rodent and porcine islet beta-cell replication, *Proc. Natl. Acad. Sci. U. S. A.* 109 (2012) 3915–3920.
- [46] N.H. Purcell, B.J. Wilkins, A. York, M.K. Saba-El-Leil, S. Meloche, J. Robbins, J.D. Molkentin, Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo, *Proc. Natl. Acad. Sci. U. S. A.* 104 (2007) 14074–14079.
- [47] X. Song, Y. Kusakari, C.Y. Xiao, S.D. Kinsella, M.A. Rosenberg, M. Scherrer-Crosbie, K. Hara, A. Rosenzweig, T. Matsui, mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy, *Am. J. Physiol. Cell Physiol.* 299 (2010) C1256–C1266.
- [48] H. Tsutsui, H. Tagawa, R.L. Kent, P.L. McCollam, K. Ishihara, M. Nagatsu, Gt Cooper, Role of microtubules in contractile dysfunction of hypertrophied cardiocytes, *Circulation* 90 (1994) 533–555.
- [49] A. Heling, R. Zimmermann, S. Kostin, Y. Maeno, S. Hein, B. Devaux, E. Bauer, W.P. Klovekorn, M. Schlepper, W. Schaper, J. Schaper, Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium, *Circ. Res.* 86 (2000) 846–853.
- [50] L.A. Aquila-Pastir, N.R. DiPaola, R.G. Matteo, N.G. Smedira, P.M. McCarthy, C.S. Moravec, Quantitation and distribution of beta-tubulin in human cardiac myocytes, *J. Mol. Cell. Cardiol.* 34 (2002) 1513–1523.
- [51] S. Balasubramanian, S.K. Mani, H. Kasiganesan, C.C. Baicu, D. Kuppuswamy, Hypertrophic stimulation increases beta-actin dynamics in adult feline cardiomyocytes, *PLoS One* 5 (2010) e11470.
- [52] J.T. Fasset, X. Hu, X. Xu, Z. Lu, P. Zhang, Y. Chen, R.J. Bache, AMPK attenuates microtubule proliferation in cardiac hypertrophy, *Am. J. Physiol. Heart Circ. Physiol.* 304 (2013) H749–H758.
- [53] E. Rapaport, Compartmentalized ATP pools produced from adenosine are nuclear pools, *J. Cell. Physiol.* 105 (1980) 267–274.